About Novo Holdings
Novo Holdings is a holding and investment company, responsible for managing the operating and financial assets of the Novo Nordisk Foundation. Headquartered in Copenhagen and wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder in Novo Nordisk and Novozymes (the “Novo Group” companies) and manages an investment portfolio (the “Investment Portfolio”), with a long-term return perspective. The Novo Holdings Investment Portfolio is comprised of two teams, namely, Life Science Investments and Novo Capital Investors. We aspire to be a leading responsible investor, recognised for delivering strong financial returns and positive societal impact. Novo Holdings operates from offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of $106 billion.
Novo Holdings is among the world’s leading life science investors and invests in companies at all stages of development. The Life Science Investments team includes Novo Seeds, Novo Ventures, Novo Growth and Principal Investments. In 2021 Life Science Investments invested $2.2 billion in 71 companies. The Novo Capital Investors team manages a broad portfolio of equities, bonds, real estate and infrastructure assets, as well as private equity investments… Continue reading about Novo Holdings here.